BioMarin Pharmaceutical Inc. (BMRN) Balance Sheet

The jump in goodwill from $196.2M to $666.4M and the debt-to-equity ratio moving from 0.11 to 0.67 suggest the company has traded a near-debt-free position for substantial acquisition leverage. Whether this strengthens the franchise depends on integration execution, which the reported net loss of $122.8M in Q3 2026 suggests is not yet translating into earnings. Investors should monitor whether the balance sheet stabilizes as integration costs roll off.

The step-up in debt appears to be acquisition-funded, and its serviceability depends on whether operating cash flow of $188.2M in Q3 2026 proves repeatable. Because the quarter also carried a net loss, the coverage of interest obligations from earnings is currently weak. Refinancing terms and maturity profile are not disclosed in the supplied data, so this warrants further investigation.

A current ratio near 2.4 suggests short-term obligations remain comfortably covered by current assets, but the reduction in cash balance signals that the buffer is shrinking. Given acquisition outflows of roughly $5.1B in Q2 2026, the cash position appears sensitive to any slowdown in collections. Investors may wish to monitor whether cash stabilizes as the integration phase matures.

Equity remained near $6.3B, supported largely by the acquisition, so the headline book value masks a deteriorating earnings component. The reversal in retained earnings suggests that stock-based compensation of $53.5M per quarter is layered onto operating losses rather than offset by profits. Dilution from share-based pay may therefore warrant closer scrutiny than the stable equity total implies.